growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC
growth protocol: grown in EMEM (Wisent) supplemented with 1 mM sodium pyruvate and MEM nonessential amino acid (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC
cell type: immortalized normal skin fibroblast
growth protocol: grown in alpha-MEM (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC
cell type: immortalized normal ovarian fibroblast
growth protocol: grown in OSE medium (Wisent) , supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC
treatment: Treated with siRNA targeting NOP58 (CUUCUACCGUUCAGAUUCU). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.
treatment: Treated with siRNA targeting NOP58 (GACAAGUCCCAAACACAAA). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.
treatment: Treated with siRNA targeting RBFOX2 (GAUGGUCACACCAUAUGCA). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.
treatment: Treated with siRNA targeting RBFOX2 (CACCUCCGCAGAAUGGAAU). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.